Liberty Wealth Management LLC has recently announced that it has increased stake in Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) by 134.22%. After grabbing 0.35 million shares, the institutional investor is now in possession of 0.2 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 0.78% having worth around $53951.0. Moreover, Geode Capital Management LLC increased its share by 35071.0 to have a control over 0.31 million shares. And GTS Securities LLC raised its holdings to 0.2 million shares by acquiring 0.2 million shares or 0.45% of the stake.
Brainstorm Cell Therapeutics, Inc. (BCLI) concluded trading on 11/30/23 at a closing price of $0.28, with 8.4 million shares of worth about $2.35 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -90.21% during that period and on Thursday the price saw a gain of about 26.82%. Currently the company’s common shares owned by public are about 48.98M shares, out of which, 39.59M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 1 analysts are covering the BCLI stock and their offered price forecasts bring an average price target of $10.00. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $10.00 and could fall to a lowest price of $10.00. The stock’s current price level is 97.2% above of average price target set by the analysts, while a rise to estimated low would result in gain of 97.2% for the stock. However, touching the estimated high of $10.00 would mean a gain of 97.2% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 8 times over the past 12 months. They bought 309,684 shares in 8 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
Vanguard Total Stock Market ETF, Vanguard Extended Market Index Fu, and Fidelity Extended Market Index Fu are the top 3 mutual funds which are holding stakes in Brainstorm Cell Therapeutics, Inc. Vanguard Total Stock Market ETF is currently holding 0.95 million shares of worth totaling $0.15 million. The company recently came buying 0.0 shares which brought its stake up to 2.11% of the company’s outstanding shares. Fidelity Extended Market Index Fu, after buying 0.18 million shares, have now control over 0.41% of the stake in the company. It holds 34619.0 shares of worth $28122.0.
Brainstorm Cell Therapeutics, Inc. (NASDAQ: BCLI) started trading at $0.23, above $0.01 from concluding price of the previous day. However, the stock later moved at a day high price of 0.2929, or with a gain of 26.82%. Stock saw a price change of 8.94% in past 5 days and over the past one month there was a price change of 82.35%. Year-to-date (YTD), BCLI shares are showing a performance of -82.99% which decreased to -82.45% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.13 but also hit the highest price of $3.46 during that period. The average intraday trading volume for Brainstorm Cell Therapeutics, Inc. shares is 2.46 million. The stock is currently trading 47.47% above its 20-day simple moving average (SMA20), while that difference is up 11.40% for SMA50 and it goes to -83.69% lower than SMA200.
Liberty Wealth Management LLC acquired 0.35 million shares of Brainstorm Cell Therapeutics, Inc. having value of about $53951.0. Data submitted at the U.S SEC by Liberty Wealth Management LLC revealed that the firm now holds 0.2 million shares in the company valued at close to $56579.32, or have control over 134.22% stake in the company. Brainstorm Cell Therapeutics, Inc. (NASDAQ: BCLI) currently have 48.98M outstanding shares and institutions hold larger chunk of about 9.88% of that. Holding of mutual funds in the company is about 4.13% while other institutional holders and individual stake holders have control over 6.62% and 12.55% of the stake respectively.
The stock has a current market capitalization of $13.67M and its 3Y-monthly beta is at -0.05. It has posted earnings per share of -$0.44 in the same period. It has Quick Ratio of 0.24. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BCLI, volatility over the week remained 17.40% while standing at 16.39% over the month.
Analysts are in expectations that Brainstorm Cell Therapeutics, Inc. (BCLI) stock would likely to be making an EPS of -$0.14 in the current quarter, while forecast for next quarter EPS is -$0.15 and it is -$0.47 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.14 which is -$0.14 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.19 in the same quarter a year ago.
Analysts at 1 brokerage firms have issued recommendations for the Brainstorm Cell Therapeutics, Inc. (BCLI)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.00. Out of those 1 Wall Street analysts, 0 recommended a “Buy” rating, while 1 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Maxim Group on February 04, 2021 offering a Buy rating for the stock and assigned a target price of $12 to it.
